{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T04:13:01Z","timestamp":1745381581560,"version":"3.40.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Kaleida Troup funding to Poolakkad S Satheeshkumar"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00520-025-09353-5","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T14:13:11Z","timestamp":1742047991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Receiving immunotherapy for the treatment of advanced renal cell carcinoma is associated with higher burden of illness, coagulopathy, cardiac arrhythmia, and disparities"],"prefix":"10.1007","volume":"33","author":[{"given":"Susan","family":"Eichhorn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel B.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Rajesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1033-6627","authenticated-orcid":false,"given":"Poolakkad S.","family":"Satheeshkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"issue":"10","key":"9353_CR1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.urolonc.2021.06.013","volume":"39","author":"A Rambhia","year":"2021","unstructured":"Rambhia A, Patel RD, Okhawere KE, Korn TG, Badani KK (2021) Immunotherapy for metastatic renal cell carcinoma: a brief history, current trends, and future directions. Urol Oncol 39(10):664\u2013677. https:\/\/doi.org\/10.1016\/j.urolonc.2021.06.013","journal-title":"Urol Oncol"},{"issue":"5","key":"9353_CR2","doi-asserted-by":"publisher","first-page":"CD011673","DOI":"10.1002\/14651858.CD011673.pub2","volume":"5","author":"S Unverzagt","year":"2017","unstructured":"Unverzagt S, Moldenhauer I, Nothacker M, Ro\u00dfmei\u00dfl D, Hadjinicolaou AV, Peinemann F, Greco F, Seliger B (2017) Immunotherapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev. 5(5):CD011673. https:\/\/doi.org\/10.1002\/14651858.CD011673.pub2","journal-title":"Cochrane Database Syst Rev."},{"key":"9353_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euros.2021.12.007","volume":"37","author":"NA Bosma","year":"2022","unstructured":"Bosma NA, Warkentin MT, Gan CL, Karim S, Heng DYC, Brenner DR, Lee-Ying RM (2022) Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Open Sci 37:14\u201326. https:\/\/doi.org\/10.1016\/j.euros.2021.12.007","journal-title":"Eur Urol Open Sci"},{"issue":"9","key":"9353_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, OyervidesJu\u00e1rez VM, Hsieh JJ, Basso U, Shah AY, Su\u00e1rez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, \u017bo\u0142nierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ, CheckMate 9ER Investigators (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 384(9):829\u2013841. https:\/\/doi.org\/10.1056\/NEJMoa2026982","journal-title":"N Engl J Med."},{"issue":"5","key":"9353_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","volume":"39","author":"K Bi","year":"2021","unstructured":"Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, DelloStritto L, Bouchard G, Steinharter J, Tewari AK, Vokes NI, Shannon E, Sun M, Park J, Chang SL, McGregor BA, Haq R, Denize T, Signoretti S, Guerriero JL, Vigneau S, Rozenblatt-Rosen O, Rotem A, Regev A, Choueiri TK, Van Allen EM (2021) Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell 39(5):649-661.e5. https:\/\/doi.org\/10.1016\/j.ccell.2021.02.015","journal-title":"Cancer Cell"},{"issue":"7","key":"9353_CR6","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers16071440","volume":"16","author":"S Casagrande","year":"2024","unstructured":"Casagrande S, Sopetto GB, Bertalot G, Bortolotti R, Racanelli V, Caffo O, Giometto B, Berti A, Veccia A (2024) Immune-related adverse events due to cancer immunotherapy: immune mechanisms and clinical manifestations. Cancers (Basel) 16(7):1440. https:\/\/doi.org\/10.3390\/cancers16071440","journal-title":"Cancers (Basel)"},{"issue":"7","key":"9353_CR7","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.mayocp.2019.03.012","volume":"94","author":"JA Marin-Acevedo","year":"2019","unstructured":"Marin-Acevedo JA, Chirila RM, Dronca RS (2019) Immune checkpoint inhibitor toxicities. Mayo Clin Proc 94(7):1321\u20131329. https:\/\/doi.org\/10.1016\/j.mayocp.2019.03.012","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"9353_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12032-023-02267-4","volume":"41","author":"P Kejamurthy","year":"2023","unstructured":"Kejamurthy P, Devi KTR (2023) Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview. Med Oncol 41(1):40. https:\/\/doi.org\/10.1007\/s12032-023-02267-4","journal-title":"Med Oncol"},{"issue":"3","key":"9353_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100049","volume":"1","author":"JJ Joseph","year":"2020","unstructured":"Joseph JJ, Rajan A, Gulley JL, Ito S, Kessler CM (2020) Acquired coagulopathy with immune checkpoint inhibitors: an underrecognized association between inflammation and coagulation. JTO Clin Res Rep 1(3):100049. https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100049","journal-title":"JTO Clin Res Rep"},{"key":"9353_CR10","unstructured":"HCUP-US. NIS Overview.https:\/\/www.hcup-us.ahrq.gov\/nisoverview.jsp. Accessed and obtained February 25, 2020"},{"key":"9353_CR11","doi-asserted-by":"crossref","unstructured":"Elixhausern A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36(1):8\u201327 JSTOR. https:\/\/www.jstor.org\/stable\/3766985. Accessed 25 Feb 2020","DOI":"10.1097\/00005650-199801000-00004"},{"issue":"6","key":"9353_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.19535","volume":"5","author":"T Ermer","year":"2022","unstructured":"Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MC, Kaminski MF, Pichert MD, Zhan PL, Mase V, Kluger H, Boffa DJ (2022) Association between food and drug administration approval and disparities in immunotherapy use among patients with cancer in the US. JAMA Netw Open 5(6):e2219535. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.19535","journal-title":"JAMA Netw Open"},{"key":"9353_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, MalekiVareki S, Fernandes R (2021) Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors\u2014a systematic review and meta-analysis. Cancer Treat Rev 92:102134. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102134","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"9353_CR14","doi-asserted-by":"publisher","first-page":"e1205","DOI":"10.1002\/onco.13812","volume":"26","author":"S George","year":"2021","unstructured":"George S, Bell EJ, Zheng Y, Kim R, White J, Devgan G, Smith J, Lal LS, Engel-Nitz NM, Liu FX (2021) The impact of adverse events on health care resource utilization, costs, and mortality among patients treated with immune checkpoint inhibitors. Oncologist 26(7):e1205\u2013e1215. https:\/\/doi.org\/10.1002\/onco.13812","journal-title":"Oncologist"},{"issue":"26","key":"9353_CR15","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"issue":"6","key":"9353_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/CJI.0000000000000264","volume":"42","author":"W Haque","year":"2019","unstructured":"Haque W, Verma V, Butler EB, Teh BS (2019) Racial and socioeconomic disparities in the delivery of immunotherapy for metastatic melanoma in the United States. J Immunother 42(6):228\u2013235. https:\/\/doi.org\/10.1097\/CJI.0000000000000264","journal-title":"J Immunother"},{"issue":"19","key":"9353_CR17","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1002\/cncr.30146","volume":"122","author":"TL Rose","year":"2016","unstructured":"Rose TL, Deal AM, Krishnan B, Nielsen ME, Smith AB, Kim WY, Milowsky MI (2016) Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era. Cancer 122(19):2988\u20132995. https:\/\/doi.org\/10.1002\/cncr.30146","journal-title":"Cancer"},{"key":"9353_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_323523","volume":"41","author":"RU Osarogiagbon","year":"2021","unstructured":"Osarogiagbon RU, Sineshaw HM, Unger JM, Acu\u00f1a-Villaordu\u00f1a A, Goel S (2021) Immune-based cancer treatment: addressing disparities in access and outcomes. Am Soc Clin Oncol Educ Book 41:1\u201313. https:\/\/doi.org\/10.1200\/EDBK_323523","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"9353_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.trecan.2022.10.002","volume":"9","author":"S Yao","year":"2023","unstructured":"Yao S, Ambrosone CB, Osarogiagbon RU, Morrow GR, Kamen C (2023) A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy. Trends Cancer 9(1):6\u20138. https:\/\/doi.org\/10.1016\/j.trecan.2022.10.002","journal-title":"Trends Cancer"},{"key":"9353_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev-med-070119-120305","volume":"72","author":"JA Freedman","year":"2021","unstructured":"Freedman JA, Al Abo M, Allen TA, Piwarski SA, Wegermann K, Patierno SR (2021) Biological aspects of cancer health disparities. Annu Rev Med 72:229\u2013241. https:\/\/doi.org\/10.1146\/annurev-med-070119-120305","journal-title":"Annu Rev Med"},{"issue":"30","key":"9353_CR21","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.1200\/JCO.22.02180","volume":"41","author":"M Canavan","year":"2023","unstructured":"Canavan M, Wang X, Ascha M, Miksad R, Showalter TN, Calip G, Gross CP, Adelson K (2023) End-of-life systemic oncologic treatment in the immunotherapy era: the role of race, insurance, and practice setting. J Clin Oncol 41(30):4729\u20134738. https:\/\/doi.org\/10.1200\/JCO.22.02180","journal-title":"J Clin Oncol"},{"issue":"2","key":"9353_CR22","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1503\/cmaj.180870","volume":"191","author":"K Esfahani","year":"2019","unstructured":"Esfahani K, Meti N, Miller WH Jr, Hudson M (2019) Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ 191(2):E40\u2013E46. https:\/\/doi.org\/10.1503\/cmaj.180870","journal-title":"CMAJ"},{"key":"9353_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86. https:\/\/doi.org\/10.3389\/fonc.2018.00086","journal-title":"Front Oncol"},{"issue":"8","key":"9353_CR24","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/jnci\/djab015","volume":"113","author":"ZW Veitch","year":"2021","unstructured":"Veitch ZW, Shepshelovich D, Gallagher C, Wang L, Abdul Razak AR, Spreafico A, Bedard PL, Siu LL, Minasian L, Hansen AR (2021) Underreporting of symptomatic adverse events in phase I clinical trials. J Natl Cancer Inst 113(8):980\u2013988. https:\/\/doi.org\/10.1093\/jnci\/djab015","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"9353_CR25","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.eprac.2024.05.014","volume":"30","author":"M Han","year":"2024","unstructured":"Han M, Jiang L, Zhao B, Liu X, Yang C, Chen W (2024) Immune checkpoint inhibitors-associated diabetes and ketoacidosis were found in FDA adverse event reporting system: a real-world evidence database study. Endocr Pract 30(9):887\u2013892. https:\/\/doi.org\/10.1016\/j.eprac.2024.05.014","journal-title":"Endocr Pract"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09353-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09353-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09353-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T07:10:50Z","timestamp":1745305850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09353-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["9353"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09353-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"1. This study is not required or mandate from the Institutional Review Board approval because it used publicly available data that had been de-identified or contain limited data set (The Healthcare Cost and Utilization Project (HCUP) does not require that users receive IRB review from their institutions). Hence, a patient consent is not possible. Further this study included only adults\u2009>\u200918\u00a0years age.2. As per the HCUP agreement it is not required that users receive IRB review from their institutions, the HCUP Data Use Agreement (DUA) provide the proof of compliance with the HIPAA privacy rule. In addition, the HCUP databases are consistent with the definition of \u201climited data sets\u201d () under the HIPAA Privacy Rule. They contain no direct patient identifiers, and completion of both the HCUP Data Use Agreement (DUA) training (), and a signed or electronically submitted DUA are required to obtain the HCUP databases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We want to disclose the role of one of the co-authors (Joel B Epstein) as an Editor of the journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"285"}}